Table 2.

Changes of gene expression in LNCaP cells^*

Symbol	Gene description	R1881	R1881 + 5b
TMPRSS2	transmembrane protease, serine 2	22.7	7.0
FKBP5	FK506 binding protein 5	29.7	5.3
HPGD	hydroxyprostaglandin dehydrogenase 15-(NAD)	70.8	13.9
KLK2	kallikrein-related peptidase 2	423.8	159.3
NDRG1	N-myc downstream regulated 1	8.6	3.9
IGF1	insulin-like growth factor 1	19.0	5.0
EAF2	ELL associated factor 2	20.5	1.6
CXCR4	chemokine (C-X-C motif) receptor 4	7.1	2.7
CXCL5	chemokine (C-X-C motif) ligand 5	15.1	2.6
CXCL9	chemokine (C-X-C motif) ligand 9	18.7	3.4
KCNMA1	potassium large conductance calcium-activated channel, subfamily M, alpha member 1	5.1	2.5
PHLDB2	pleckstrin homology-like domain, family B, member 2	6.8	2.8
SOCS2	suppressor of cytokine signaling 2	6.4	2.3
SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	10.3	0.5

^*LNCaP cells were treated with DMSO or 5b (5 μM) in the absence or presence of synthetic androgen R1881 (0.5 nM) for 20 hr, cDNA microarray was performed using the GeneChip Human Genome U133 Plus 2.0 Array. The values shown represent fold-changes compared to DMSO-treated control cells.